PMID- 31132977
OWN - NLM
STAT- MEDLINE
DCOM- 20200212
LR  - 20200212
IS  - 2212-3911 (Electronic)
IS  - 1574-8863 (Print)
IS  - 1574-8863 (Linking)
VI  - 14
IP  - 3
DP  - 2019
TI  - Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung 
      Adenocarcinoma.
PG  - 225-229
LID - 10.2174/1574886314666190528121039 [doi]
AB  - BACKGROUND: Immune checkpoint inhibitors (CPIs) are new promising anti-cancer 
      drugs that block negative costimulation of T-cells leading to an enhanced 
      anti-tumor immune response. Pembrolizumab, an a monoclonal antibody, targeting 
      the programmed cell death protein 1 (PD-1) pathway. CPIs have been associated 
      with a number of immune-related adverse events (AEs), including musculoskeletal 
      and rheumatic disease. OBJECTIVE: To present a case with lung adenocarcinoma 
      treated with pembrolizumab, which developed inflammatory arthritis and fasciitis. 
      CASE REPORT: A 73-year-old male patient was referred to the rheumatology 
      outpatient clinic with complaints of pain in the pretibial area, pain and 
      swelling in both ankles joints and the right first metacarpophalangeal (MCP) 
      joint. Three months ago he had diagnosed with lung adenocarcinoma and 
      pembrolizumab was started. Locomotor system complaints were started after 
      receiving two infusions of pembrolizumab. Physical examination revealed both 
      ankle arthritis, mild edema in the pretibial region, tenderness in the muscles 
      and arthritis in the right first MCP joint. Laboratory examinations showed mild 
      acute phase reactants elevation. Lower extremity MRI showed diffuse edema in both 
      gastrocnemius muscle and fascia, compatible with fasciitis. Pembrolizumab-related 
      fasciitis and seronegative arthritis were diagnosed. Low dose corticosteroid was 
      started and a significant regression was observed in the patient's complaints. 
      CONCLUSION: Inflammatory myositis with fasciitis and inflammatory arthritis in 
      lower extremities appears to be a new adverse effect of pembrolizumab therapy.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Kobak, Senol
AU  - Kobak S
AD  - Istinye University Faculty of Medicine, LIV Hospital, Department of Rheumatology, 
      Istanbul, Turkey.
LA  - eng
PT  - Case Reports
PL  - United Arab Emirates
TA  - Curr Drug Saf
JT  - Current drug safety
JID - 101270895
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - *Adenocarcinoma of Lung/drug therapy
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/*adverse effects/therapeutic use
MH  - Arthritis/*chemically induced/diagnostic imaging
MH  - Humans
MH  - *Lung Neoplasms/drug therapy
MH  - Male
PMC - PMC6864613
OTO - NOTNLM
OT  - Immune checkpoint inhibitor
OT  - arthritis
OT  - fasciitis
OT  - lung adenocarcinoma
OT  - pembrolizumab
OT  - rheumatic feature.
EDAT- 2019/05/28 06:00
MHDA- 2020/02/13 06:00
PMCR- 2019/11/20
CRDT- 2019/05/29 06:00
PHST- 2019/04/27 00:00 [received]
PHST- 2019/05/14 00:00 [revised]
PHST- 2019/05/21 00:00 [accepted]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2020/02/13 06:00 [medline]
PHST- 2019/05/29 06:00 [entrez]
PHST- 2019/11/20 00:00 [pmc-release]
AID - CDS-EPUB-98643 [pii]
AID - CDS-14-225 [pii]
AID - 10.2174/1574886314666190528121039 [doi]
PST - ppublish
SO  - Curr Drug Saf. 2019;14(3):225-229. doi: 10.2174/1574886314666190528121039.